Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving pazopanib works in treating patients with
recurrent or metastatic invasive breast cancer. Pazopanib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth and by blocking blood flow to the
tumor.